Hypercalcaemia due to Sarcoidosis during Treatment with Avelumab for Metastatic Merkel Cell Carcinoma
Merkel cell carcinoma is a rare but aggressive skin cancer. Response to chemotherapy is not durable but avelumab, an anti-PD-L1 inhibitor, showed promising ongoing response in a phase II trial. Checkpoint inhibitors including avelumab are known to cause overactivation of the immune system, leading t...
Main Authors: | Sandy Tun Min, Ina I.C. Nordman, Huy A. Tran |
---|---|
Format: | Article |
Language: | English |
Published: |
Karger Publishers
2019-08-01
|
Series: | Case Reports in Oncology |
Subjects: | |
Online Access: | https://www.karger.com/Article/FullText/502285 |
Similar Items
-
Avelumab for the treatment of locally advanced or metastatic Merkel cell carcinoma—A multicenter real‐world experience in Israel
by: Itamar Averbuch, et al.
Published: (2023-06-01) -
Case Report: Clinical Experience With Avelumab in Patients With Metastatic Merkel Cell Carcinoma and Brain Metastases Treated in Europe
by: Kate Fife, et al.
Published: (2021-05-01) -
Budget impact model of avelumab in patients with metastatic merkel cell carcinoma in the US
by: Bharmal M, et al.
Published: (2019-05-01) -
A cost‐utility analysis of avelumab for metastatic Merkel cell carcinoma in Taiwan
by: Wen‐Cheng Chang, et al.
Published: (2021-12-01) -
Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial
by: Howard L. Kaufman, et al.
Published: (2018-01-01)